Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, talks to Pharma’s Almanac about pluripotent stem cells and how the company speeds up the R&D process by delivering Ready to Differentiate® cells. Watch the video to hear more from Ben, including his take on the next big thing in pharma.
Pluristyx Featured in Labroots Webinar
September 4, 2022
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, presented to webinar participants the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and the manufacturing workflow, beginning with the starting cell source and MCB